Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
although Amgen has also reported positive pivotal trial results in KRAS G12C-mutated colorectal cancer for Lumakras in combination with its own EGFR drug Vectibix (panitumumab). The CRC approval ...
Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS ...
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...
Hosted on MSN1mon
FDA approves Amgen’s combo therapy for colorectal cancer“This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer." The trial, which enrolled 160 ...
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...
Vectibix (panitumumab), for treating KRAS G12C-mutated metastatic colorectal cancer (mCRC). The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results